Black Diamond Therapeutics, Inc.
TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE

Abstract:

The present disclosure relates to new compounds of formula I ##STR00001## and pharmaceutically acceptable salts and stereoisomers thereof, as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of abnormal cell growth in mammals, (e.g., humans).